MSD Initiated Phase I Trial Using Cyprumed Oral Tech
The trial marks the first human development program utilizing Cyprumed's oral delivery platform for peptide-based drugs.
Updated on Sept. 29, 2026 in Biotech
Live Poll
Do you believe oral pill alternatives for complex injectable medications will improve your daily life?
MSD has officially initiated a Phase I clinical trial using an oral tablet technology developed by the Austrian firm Cyprumed. This development represents the first time Cyprumed's drug delivery platform has entered human clinical testing.
Why it matters
The collaboration seeks to solve historical challenges in peptide administration by enabling oral delivery that maintains consistent drug exposure despite dietary variations. This approach aims to replace traditional injectable methods with a more scalable and patient-friendly oral formulation.
Cyprumed's platform uses established pharmaceutical excipients—inactive substances used as carriers—to stabilize peptides for oral uptake. The technology is engineered to optimize bioavailability compared to standard formulation approaches.
The players
MSD
A global biopharmaceutical company based in Rahway, New Jersey, focused on the research and development of vaccines and therapeutic medicines.
Cyprumed
An Innsbruck, Austria-based biotechnology firm specializing in drug delivery systems designed to improve the oral bioavailability of peptide drugs.
The details
The oral tablet technology is designed to enable the systemic delivery of peptides, which are typically degraded by enzymes in the digestive tract. By using specific excipients, the platform facilitates absorption through the gut lining while maintaining a scalable manufacturing process. This trial marks the first time this specific chemical configuration has been evaluated in humans to demonstrate consistent drug concentration levels, particularly regarding the impact of food on absorption.
Timeline
April 2025: Cyprumed and MSD signed a non-exclusive license and option agreement.
September 29, 2026: MSD initiated the first Phase I clinical trial.
The Tech Race
The clinical trial follows the industry-wide transition from injectable to oral peptide therapeutics. This movement reflects a broader competition to develop scalable oral delivery systems for molecules that were previously limited to parenteral administration.
Patients may eventually see the replacement of injectable peptide treatments with daily oral tablets, though the timeline remains subject to successful Phase I results. Initial access will be limited to clinical trial participants until the technology completes necessary safety and efficacy studies.
The takeaway
This trial serves as the first real-world validation of Cyprumed's technology in a human clinical setting. Observers should track the progression of this MSD-led program to see if it successfully clears Phase I safety benchmarks for peptide bioavailability.
Further reading
For more on the latest research in drug delivery systems, explore our Biotech section.
More information
For more details on the drug delivery platform, visit the Cyprumed company website.
Live Poll
Do you believe oral pill alternatives for complex injectable medications will improve your daily life?
